Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
